AFFiRiS AG's Atherosclerosis Vaccine Development Receives EU Support
The atherosclerosis vaccine development program by AFFiRiS AG (Vienna, Austria) is receiving financial support from the EU?s EuroTrans-Bio call.
The atherosclerosis vaccine development program by AFFiRiS AG (Vienna, Austria) is receiving financial support from the EU’s EuroTrans-Bio call. The project—known as CETP Vaccine (ETB-2008-28)—is based on the Affitome technology of AFFiRiS AG and is being conducted together with EMC microcollections GmbH from Tubingen, Germany.
One of the primary causes of cardiovascular disease is atherosclerosis, a narrowing of key arteries caused by fatty deposits. Although there are options for medication-based intervention in the form of statins, these are deemed to be of limited effectiveness despite some notable successes. The aim of atherosclerosis vaccination is to increase the amount of “good” high-density lipoprotein cholesterol (HDLc) in the blood and thus reduce the occurrence of harmful fatty deposits in the arteries.
Product candidates were delivered by AFFiRiS’s Affitome platform technology. The target is a protein known as CETP (cholesteryl ester transfer protein). The main item of the joint efforts of AFFiRiS and EMC is the vaccination against CETP. By transferring cholesteryl ester from HDLc to LDLc and VLDLc, this protein reduces “good” HDL and has a detrimental impact on the ratio of LDLc to HDLc.
The CETP Vaccine project is scheduled to last 30 months and will culminate in Phase 1 clinical trials. Overall, the support provided to the project by the EU is worth several hundred thousand euros, while the two project partners are bearing around half of the total costs.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
